Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
Int J Mol Sci. 2021 May 25;22(11):5574. doi: 10.3390/ijms22115574.
Over the last decades, the study of cancer metabolism has returned to the forefront of cancer research and challenged the role of genetics in the understanding of cancer development. One of the major impulses of this new trend came from the discovery of oncometabolites, metabolic intermediates whose abnormal cellular accumulation triggers oncogenic signalling and tumorigenesis. These findings have led to reconsideration and support for the long-forgotten hypothesis of Warburg of altered metabolism as oncogenic driver of cancer and started a novel paradigm whereby mitochondrial metabolites play a pivotal role in malignant transformation. In this review, we describe the evolution of the cancer metabolism research from a historical perspective up to the oncometabolites discovery that spawned the new vision of cancer as a metabolic disease. The oncometabolites' mechanisms of cellular transformation and their contribution to the development of new targeted cancer therapies together with their drawbacks are further reviewed and discussed.
在过去的几十年里,癌症代谢的研究重新成为癌症研究的前沿,并挑战了遗传学在癌症发展理解中的作用。这一新趋势的主要推动力之一来自于致癌代谢物的发现,即代谢中间产物,其异常细胞积累会引发致癌信号和肿瘤发生。这些发现导致人们重新考虑和支持瓦伯格(Warburg)关于代谢改变作为癌症致癌驱动因素的长期被遗忘的假说,并开创了一种新的范例,即线粒体代谢物在恶性转化中发挥关键作用。在这篇综述中,我们从历史角度描述了癌症代谢研究的演变,直到发现致癌代谢物,这催生了癌症作为一种代谢疾病的新观点。进一步综述和讨论了致癌代谢物的细胞转化机制及其对新的靶向癌症治疗方法发展的贡献及其缺点。